News
Synklino completes Series A raise of EUR 29.8 million to advance clinical trials of its drug candidate for the treatment of Cytomegalovirus (CMV)
PKA pension fund lead investment, alongside The Danish Growth…
ImaginAb and Roche have entered a clinical trial supply agreement for provision of atezolizumab (Tecentriq®)1 to Non-Small Cell Lung Cancer Patients Enrolled in ImaginAb’s iPREDICT Phase IIb Study
Los Angeles, California, USA, June 8th, 2022 – ImaginAb Inc.,…
Ariceum Therapeutics Launches with EUR 25M Series A to Advance Lead Asset, Satoreotide, for the Treatment of Low- and High-Grade Neuroendocrine Cancers
Oversubscribed financing co-led by HealthCap and EQT Life Sciences…
Bionical Solutions Bolsters Clinical Services Team
Willington, UK, 7 June 2022 – Bionical Solutions, a leading…
Verona Pharma to Host KOL Event on June 16, 2022
LONDON and RALEIGH, N.C., June 06, 2022 (GLOBE NEWSWIRE) -- Verona…
Destiny Pharma plc – Result of Annual General Meeting and Strategy Update
Brighton, United Kingdom - 27 May 2022 - Destiny Pharma plc…
Destiny Pharma appoints three Non-Executive Directors
Brighton, United Kingdom - 26 May 2022 - Destiny Pharma plc…
ENHANC3D GENOMICS Awarded QuickFire Challenge Grant
Cambridge, UK – 26 May 2022: ENHANC3D GENOMICS (“Enhanc3D”), a biotechnology company unlocking the full potential of the human 3D genome to accelerate patient-centric medicine, announces it has been selected as one of the awardees under Johnson & Johnson Innovation’s Immunology Innovations QuickFire Challenge.
ImaginAb and [Yantai] DongCheng Pharmaceutical Group Sign Exclusive License Agreement to Commercialize CD8 ImmunoPET Agent in China to Serve Pharma and Healthcare Community
Los Angeles, USA and Yantai, China – May 24th, 2022 - ImaginAb,…
Futura Announces Collaboration with Cooper Consumer Health to Commercialise MED3000 in EEA, United Kingdom and Switzerland
Futura Medical plc (AIM: FUM), a pharmaceutical company developing…
Novo Holdings Portfolio Company F2G enters strategic collaboration with Shionogi to commercialise its new antifungal agent Olorofim in Europe and Asia
Deal value includes upfront payment of US$100 million with…
DelSiTech and Anticancer Bioscience Announce a Collaboration Agreement for the Development of Long-acting Therapies in Oncology
Turku, Finland – 18 May 2022: DelSiTech Ltd, the leading silica…
Sofinnova Partners and Apollo form strategic partnership in life sciences
NEW YORK & PARIS (May 16, 2022) - Apollo (NYSE: APO) and Sofinnova…
Shionogi Co., Ltd. and F2G Enter Strategic Collaboration to Develop and Commercialize the New Antifungal Agent Olorofim in Europe and Asia
Shionogi to conduct clinical trials, subsequent registration,…
Destiny Pharma – World leading C. difficile scientists to present landmark data on the ability of NTCD-M3 to colonise the gut after antibiotic administration
Brighton, United Kingdom – 12 May 2022 – Destiny Pharma…
Rejuvenate Biomed appoints life sciences leader Dr. Ajit Shetty as Chair of the Board of Directors to help guide international ambitions
Diepenbeek, Belgium, 12 May 2022 – Rejuvenate Biomed NV (“Rejuvenate”),…
ImaginAb announces a new supply agreement with Invicro to offer clinical doses of CD8 investigational ImmunoPET imaging agent for Immuno-Oncology preclinical and clinical studies
Inglewood, California, May 12th, 2022 - ImaginAb Inc., a market-leading…
Novo Holdings backs animal health company Invetx
Novo Holdings today announces it has participated in a $60.5…
vasopharm GmbH Announces Brain Glutamate Microdialysate Data from Post Hoc Analyses of Clinical Trials in Traumatic Brain Injury
Ronopterin significantly reduces glutamate levels measured…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York
